Tempest Therapeutics Inc

+0.13 (+6.05%)
Regulatory, Other Pre-Announcement

Tempest Provides Asco Kol Feedback On Tpst-1120 Clinical Results And Updated Financial Guidance

Published: 06/09/2022 12:08 GMT
Tempest Therapeutics Inc (TPST) - Tempest Provides Asco Kol Feedback on Tpst-1120 Clinical Results and Updated Financial Guidance.
Tempest Therapeutics - Recist Responses Seen With Tpst-1120 Combined With Anti-pd1 Therapy in Patients Who Previously Progressed on Anti-pd1/pdl1 Therapy.
Tempest Therapeutics Inc - Potential Biomarker for Patient Responsiveness to Tpst-1120 Identified and Will Be Further Explored.
Tempest Therapeutics Inc - Tpst-1120 Demonstrated Ability to Reprogram Tme in a Tumor Type Refractory to Anti-pd1 With Low Tumor Mutation Burden.
Tempest Therapeutics Inc - Tpst-1120 Demonstrated Monotherapy Clinical Benefit in Patients With Late-line Advanced, Poor-prognosis Cancers.
Tempest Therapeutics Inc - Tpst-1120 Was Well Tolerated As Both a Monotherapy and in Combination With Nivolumab.
Tempest Therapeutics Inc - Cash and Cash Equivalents Are Currently Expected to Be Sufficient to Fund Its Current Operating Plans Into Q1 of 2024.